Search research articles
Contact Us
Filters
Showing results (231-240 of 257) with videos related to
Page
of 26
Sort By:
Blood
|
January 11, 2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Xavier Leleu, Lionel Karlin, Margaret Macro, et al.
The Lancet. Haematology
|
November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
The New England Journal of Medicine
|
September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood
|
October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
Blood Cancer Journal
|
October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Philippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
The Lancet. Oncology
|
October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Salomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 257) with videos related to
Sort By:
Page
of 26
Blood
|
January 11, 2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Xavier Leleu, Lionel Karlin, Margaret Macro, et al.
The Lancet. Haematology
|
November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
The New England Journal of Medicine
|
September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood
|
October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
Blood Cancer Journal
|
October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Philippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
The Lancet. Oncology
|
October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Salomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Page
of 26